AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$ATR

Touya Gael sold $500K of ATR

Touya Gael (Segment Pres., CEO Designate) sold 3,740 shares of APTARGROUP, INC. (ATR) at an average of $133.76 ($133.69–$134.55, $0.50M total) across 2 trades on 2026-08-27.

Original reporting
SEC EDGAR · Touya Gael
Published Aug 28, 2026, 2:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 3:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ATR
Bearish
medium confidence
Mentioned
$ATR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATRBearishLow
01

Why it matters

The disclosed sale reduces insider ownership, which may be interpreted as reduced confidence, but the amount is small relative to ATR's float.

02

Market read

Routine insider sale with modest size; limited trading relevance.

03

What to watch

No 10b5‑1 plan; timing may align with personal tax planning.

Relevance 5/10Novelty 3/10Timing: post‑market on 2026‑08‑27

Background

Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$ATRBearishMedium confidence
Context

CEO-designate Touya Gael sold 3,740 shares for $500,276, reducing his stake to 29,102 shares.

Expected impact

Potential slight dip in ATR price.

Evidence & confidence

Sale size is modest relative to market cap, but insider status adds weight.

Market effects

Sector

Minimal impact on packaging and dispensing sector.

Regional

No regional effect beyond investor sentiment.

Global

Limited to ATR shareholders.

Counterpoint

What could challenge this read

Sale could be routine liquidity need, not a bearish signal.

Key entities

  • Company
    AptarGroup, Inc.

    Manufacturer of dispensing and packaging solutions, ticker ATR.

  • Individual
    Touya Gael

    Segment President and CEO Designate of AptarGroup.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ATR insider trading history →

Related articles

$ATRHighAI 8/10

Aptar Q3 2026 slides: broad growth, strong Pharma pipeline

AptarGroup (NYSE:ATR) reported Q3 2026 sales of $1.019B, up 6% YoY, with adjusted EPS of $1.52 beating estimates. Growth was seen across all segments, but margins were pressured. The Pharma segment grew 2% reported, 1% core, while Beauty grew 9% reported, 8% core, and Closures grew 11%. Management expects Q4 adjusted EPS of $1.39-$1.47, up 17% YoY.

investing.com
$ATRMed

AptarGroup Inc (ATR) (Q3 2026) Earnings Call Highlights: Core Sales Grow 5% as Pharma

AptarGroup Inc (ATR) reported Q3 2026 core sales growth of 5% across all segments, with Pharma, Beauty, and Closures up 8%, 8%, and 11% respectively. Adjusted EPS was $1.52, down 6% YoY. Pharma growth was impacted by emergency medicine destocking, expected to affect full-year sales by $65M. Beauty and Closures margins declined due to operational challenges. CEO Gael Touya outlined plans for multi-year transformation in Beauty and reiterated long-term growth targets for Pharma.

finance.yahoo.com
$ATRMedAI 8/10

What AptarGroup (ATR) Said on Its Q3 Earnings Call

AptarGroup (ATR) reported Q3 earnings, highlighting growth in beauty, closures, and pharma sectors. Beauty core sales rose 8%, while closures saw 11% growth. Pharma developments include collaborations and acquisitions. The company recorded a $61.2M charge related to its Russian subsidiary. ATR forecasted Q4 adjusted EPS of $1.39-$1.47, up 17% YoY. Full-year capex is expected at $260M-$280M. Virginie Maes will lead Aptar Pharma starting January 1.

finance.yahoo.com